This report reinforces therecommendations14 that all patients with the severe and/or critical form of COVID-19 bescreened as to the presence of hyperinflammation, using laboratory biomarkers (forinstance, ferritin dosage, CRP, blood sedimentation rate, (BSR) among others), andidentifying the subgroup of patients for whom immunosuppression may increase thechances of mortality. The gene discussed is CRP; the disease is COVID-19.